Connection

LAWRENCE DONEHOWER to Humans

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Humans.
Connection Strength

0.419
  1. WIP1 dephosphorylation of p27Kip1 Serine 140 destabilizes p27Kip1 and reverses anti-proliferative effects of ATM phosphorylation. Cell Cycle. 2020 02; 19(4):479-491.
    View in: PubMed
    Score: 0.019
  2. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019 07 30; 28(5):1370-1384.e5.
    View in: PubMed
    Score: 0.018
  3. Phosphatases reverse p53-mediated cell cycle checkpoints. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7172-3.
    View in: PubMed
    Score: 0.013
  4. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat. 2014 Jun; 35(6):715-27.
    View in: PubMed
    Score: 0.012
  5. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.
    View in: PubMed
    Score: 0.012
  6. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol. 2013 Jan; 229(1):99-110.
    View in: PubMed
    Score: 0.012
  7. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses. Mol Cancer Res. 2012 Jun; 10(6):845-55.
    View in: PubMed
    Score: 0.011
  8. Dephosphorylation of ?-H2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle. 2010 Jun 01; 9(11):2092-6.
    View in: PubMed
    Score: 0.010
  9. The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair. DNA Repair (Amst). 2010 Jul 01; 9(7):813-23.
    View in: PubMed
    Score: 0.010
  10. Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J Biol Chem. 2010 Apr 23; 285(17):12935-47.
    View in: PubMed
    Score: 0.009
  11. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 11; 9(11):831-41.
    View in: PubMed
    Score: 0.009
  12. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009 Mar 15; 69(6):2559-67.
    View in: PubMed
    Score: 0.009
  13. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 2008 Jun; 27(2):123-35.
    View in: PubMed
    Score: 0.008
  14. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability. Cell Cycle. 2008 Jan 15; 7(2):164-8.
    View in: PubMed
    Score: 0.008
  15. Decline and fall of the tumor suppressor. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18347-8.
    View in: PubMed
    Score: 0.008
  16. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev. 2007 Nov-Dec; 128(11-12):717-30.
    View in: PubMed
    Score: 0.008
  17. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007 Oct; 12(4):342-54.
    View in: PubMed
    Score: 0.008
  18. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle. 2007 Jan 01; 6(1):52-5.
    View in: PubMed
    Score: 0.008
  19. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle. 2005 Aug; 4(8):1060-4.
    View in: PubMed
    Score: 0.007
  20. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005 Aug 25; 576(1-2):4-21.
    View in: PubMed
    Score: 0.007
  21. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005 May 15; 19(10):1162-74.
    View in: PubMed
    Score: 0.007
  22. p53: guardian AND suppressor of longevity? Exp Gerontol. 2005 Jan-Feb; 40(1-2):7-9.
    View in: PubMed
    Score: 0.007
  23. Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins. Cell Cycle. 2004 Nov; 3(11):1363-6.
    View in: PubMed
    Score: 0.007
  24. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell. 2004 Aug 27; 15(4):621-34.
    View in: PubMed
    Score: 0.006
  25. Insights into aging obtained from p53 mutant mouse models. Ann N Y Acad Sci. 2004 Jun; 1019:171-7.
    View in: PubMed
    Score: 0.006
  26. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res. 2003 Jan 28; 522(1-2):69-83.
    View in: PubMed
    Score: 0.006
  27. EPIMUTESTR: a nearest neighbor machine learning approach to predict cancer driver genes from the evolutionary action of coding variants. Nucleic Acids Res. 2022 07 08; 50(12):e70.
    View in: PubMed
    Score: 0.006
  28. Does p53 affect organismal aging? J Cell Physiol. 2002 Jul; 192(1):23-33.
    View in: PubMed
    Score: 0.006
  29. A general calculus of fitness landscapes finds genes under selection in cancers. Genome Res. 2022 05; 32(5):916-929.
    View in: PubMed
    Score: 0.005
  30. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol. 2002 Feb; 22(4):1094-105.
    View in: PubMed
    Score: 0.005
  31. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022 02 01; 15(2).
    View in: PubMed
    Score: 0.005
  32. A pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement. Nat Commun. 2021 02 10; 12(1):937.
    View in: PubMed
    Score: 0.005
  33. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics. 2000 Mar 15; 64(3):298-306.
    View in: PubMed
    Score: 0.005
  34. Mouse models in tumor suppression. Oncogene. 1998 Dec 24; 17(25):3385-400.
    View in: PubMed
    Score: 0.004
  35. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018 11 01; 23(5):700-713.e6.
    View in: PubMed
    Score: 0.004
  36. Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. Proc Natl Acad Sci U S A. 2018 10 16; 115(42):10666-10671.
    View in: PubMed
    Score: 0.004
  37. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018 04 03; 23(1):239-254.e6.
    View in: PubMed
    Score: 0.004
  38. A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production. J Virol. 1997 Nov; 71(11):8542-51.
    View in: PubMed
    Score: 0.004
  39. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. Int J Cancer. 2017 11 15; 141(10):2062-2075.
    View in: PubMed
    Score: 0.004
  40. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res. 2017 03 15; 77(6):1250-1260.
    View in: PubMed
    Score: 0.004
  41. LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro. Cell Cycle. 2017 Jan 17; 16(2):213-223.
    View in: PubMed
    Score: 0.004
  42. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer. 2016 11 08; 16(1):869.
    View in: PubMed
    Score: 0.004
  43. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep. 2016 Feb 02; 14(4):907-919.
    View in: PubMed
    Score: 0.004
  44. Genomic profiling of S?zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015 Dec; 47(12):1426-34.
    View in: PubMed
    Score: 0.004
  45. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. Br J Cancer. 2015 Nov 03; 113(9):1289-97.
    View in: PubMed
    Score: 0.003
  46. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
    View in: PubMed
    Score: 0.003
  47. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
    View in: PubMed
    Score: 0.003
  48. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One. 2015; 10(2):e0115635.
    View in: PubMed
    Score: 0.003
  49. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. Nat Commun. 2014 Nov 20; 5:5274.
    View in: PubMed
    Score: 0.003
  50. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec; 46(12):1267-73.
    View in: PubMed
    Score: 0.003
  51. Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014 Sep 08; 26(3):390-401.
    View in: PubMed
    Score: 0.003
  52. Complementation of human immunodeficiency virus type 1 vif mutants in some CD4+ T-cell lines. Virus Res. 1994 Sep; 33(3):269-80.
    View in: PubMed
    Score: 0.003
  53. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 08; 26(3):319-330.
    View in: PubMed
    Score: 0.003
  54. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11145-50.
    View in: PubMed
    Score: 0.003
  55. Combinatorial therapy discovery using mixed integer linear programming. Bioinformatics. 2014 May 15; 30(10):1456-63.
    View in: PubMed
    Score: 0.003
  56. The tumor suppressor p53. Biochim Biophys Acta. 1993 Aug 23; 1155(2):181-205.
    View in: PubMed
    Score: 0.003
  57. Transcriptional and translational regulation of C/EBP?-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1a proteins at the early and late stages of liver cancer. J Biol Chem. 2013 May 17; 288(20):14451-14462.
    View in: PubMed
    Score: 0.003
  58. Activation of WIP1 phosphatase by HTLV-1 Tax mitigates the cellular response to DNA damage. PLoS One. 2013; 8(2):e55989.
    View in: PubMed
    Score: 0.003
  59. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene. 2010 Sep 02; 29(35):4938-46.
    View in: PubMed
    Score: 0.002
  60. 55K isoform of CDK9 associates with Ku70 and is involved in DNA repair. Biochem Biophys Res Commun. 2010 Jun 25; 397(2):245-50.
    View in: PubMed
    Score: 0.002
  61. The use of primers from highly conserved pol regions to identify uncharacterized retroviruses by the polymerase chain reaction. J Virol Methods. 1990 Apr; 28(1):33-46.
    View in: PubMed
    Score: 0.002
  62. Impact papers on aging in 2009. Aging (Albany NY). 2010 Mar; 2(3):111-21.
    View in: PubMed
    Score: 0.002
  63. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009 Apr 15; 18(8):1464-70.
    View in: PubMed
    Score: 0.002
  64. Identification of a conserved sequence in the non-coding regions of many human genes. Nucleic Acids Res. 1989 Jan 25; 17(2):699-710.
    View in: PubMed
    Score: 0.002
  65. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 2008 Feb; 86(3):245-56.
    View in: PubMed
    Score: 0.002
  66. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007 Aug; 5(8):e201.
    View in: PubMed
    Score: 0.002
  67. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res. 2007 May 01; 67(9):4104-12.
    View in: PubMed
    Score: 0.002
  68. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006 Sep; 5(17):2005-11.
    View in: PubMed
    Score: 0.002
  69. Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice. Carcinogenesis. 2007 Jan; 28(1):191-8.
    View in: PubMed
    Score: 0.002
  70. Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor. EMBO J. 2006 Mar 22; 25(6):1406-17.
    View in: PubMed
    Score: 0.002
  71. 53BP1 oligomerization is independent of its methylation by PRMT1. Cell Cycle. 2005 Dec; 4(12):1854-61.
    View in: PubMed
    Score: 0.002
  72. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem. 2006 Mar 17; 281(11):7089-101.
    View in: PubMed
    Score: 0.002
  73. Analysis of cellular senescence in culture in vivo: the senescence-associated beta-galactosidase assay. Curr Protoc Cell Biol. 2005 Jul; Chapter 18:18.9.1-18.9.9.
    View in: PubMed
    Score: 0.002
  74. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003 Sep; 23(17):6159-73.
    View in: PubMed
    Score: 0.002
  75. Development of an HIV-based cDNA expression cloning system. Mol Ther. 2003 Jul; 8(1):167-73.
    View in: PubMed
    Score: 0.001
  76. Generation and characterization of p53 mutant mice. Methods Mol Biol. 2003; 234:29-49.
    View in: PubMed
    Score: 0.001
  77. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem. 2000 Oct 20; 275(42):32649-57.
    View in: PubMed
    Score: 0.001
  78. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol. 2000 Sep; 165(1):184-90.
    View in: PubMed
    Score: 0.001
  79. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000 Jun 15; 14(12):1448-59.
    View in: PubMed
    Score: 0.001
  80. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.001
  81. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol. 1996 Jul; 16(7):3765-72.
    View in: PubMed
    Score: 0.001
  82. Analysis of human immunodeficiency virus type 1 integrase mutants. Virology. 1995 Aug 01; 211(1):332-5.
    View in: PubMed
    Score: 0.001
  83. Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther. 1995 May; 2(3):181-6.
    View in: PubMed
    Score: 0.001
  84. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res. 1995 May 01; 55(9):1963-70.
    View in: PubMed
    Score: 0.001
  85. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res. 1995 Apr 15; 55(8):1763-73.
    View in: PubMed
    Score: 0.001
  86. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res Hum Retroviruses. 1994 Mar; 10(3):295-301.
    View in: PubMed
    Score: 0.001
  87. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol. 1994; 18(3):207-16.
    View in: PubMed
    Score: 0.001
  88. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):9075-9.
    View in: PubMed
    Score: 0.001
  89. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 1993 Sep 10; 74(5):813-22.
    View in: PubMed
    Score: 0.001
  90. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther. 1993 Aug; 4(4):451-60.
    View in: PubMed
    Score: 0.001
  91. Studies on a type D retrovirus isolated from an AIDS patient lymphoma. AIDS Res Hum Retroviruses. 1992 May; 8(5):742-51.
    View in: PubMed
    Score: 0.001
  92. Isolation of a type D retrovirus from B-cell lymphomas of a patient with AIDS. J Virol. 1991 Nov; 65(11):5663-72.
    View in: PubMed
    Score: 0.001
  93. Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. J Virol. 1988 Nov; 62(11):4224-31.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.